研究代号 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
=== Metabolic niche partitioning === In 2010, exometabolomics analysis of the cyanobacterium, Synechococcus sp. PCC 7002 by Baran, et al. revealed that this photoautotroph could deplete a diverse pool of exogenous metabolites. A follow-up exometabolomics study on sympatric microbial isolates from biological soil crust, which exist in communities with cyanobacteria in the desert soils of the Colorado Plateau, suggested that metabolite niche partitioning exists in these communities, where each isolate only utilizes 13-26% of metabolites from the soil
=== Tempe semangit === In Indonesia, ripe tempeh (two or more days old) is considered a delicacy. Names include tempe semangit ('stinky tempeh') in Java, hampir busuk ('almost rotten') tempeh or tempe kemarin ('yesterday tempeh'). Having a slightly pungent aroma, small amounts are used as a flavoring agent in traditional Javanese sayur lodeh vegetable stew and sambal tumpang.
Nanoparticles present possible dangers, both medically and environmentally. Most of these are due to the high surface to volume ratio, which can make the particles very reactive or catalytic. They are also thought to aggregate on phospholipid bilayers and pass through cell membranes in organisms, and their interactions with biological systems are relatively unknown. However, it is unlikely the particles would enter the cell nucleus, Golgi complex, endoplasmic reticulum or other internal cellular components due to the particle size and intercellular agglomeration. A recent study looking at the effects of ZnO nanoparticles on human immune cells has found varying levels of susceptibility to cytotoxicity. There are concerns that pharmaceutical companies, seeking regulatory approval for nano-reformulations of existing medicines, are relying on safety data produced during clinical studies of the earlier, pre-reformulation version of the medicine. This could result in regulatory bodies, such as the FDA, missing new side effects that are specific to the nano-reformulation. However considerable research has demonstrated that zinc nanoparticles are not absorbed into the bloodstream in vivo. Concern has also been raised over the health effects of respirable nanoparticles from certain combustion processes. Preclinical investigations have demonstrated that some inhaled or injected noble metal nano-architectures avoid persistence in organisms. As of 2013 the U.S. Environmental Protection Agency was investigating the safety of the following nanoparticles:
The isoelectric point (pI, pH(I), IEP), is the pH at which a molecule carries no net electrical charge or is electrically neutral in the statistical mean. The standard nomenclature to represent the isoelectric point is pH(I). However, pI is also used. For brevity, this article uses pI. The net charge on the molecule is affected by pH of its surrounding environment and can become more positively or negatively charged due to the gain or loss, respectively, of protons (H+). Surfaces naturally charge to form a double layer. In the common case when the surface charge-determining ions are H+/HO−, the net surface charge is affected by the pH of the liquid in which the solid is submerged. The pI value can affect the solubility of a molecule at a given pH. Such molecules have minimum solubility in water or salt solutions at the pH that corresponds to their pI and often precipitate out of solution. Biological amphoteric molecules such as proteins contain both acidic and basic functional groups. Amino acids that make up proteins may be positive, negative, neutral, or polar in nature, and together give a protein its overall charge. At a pH below their pI, proteins carry a net positive charge; above their pI they carry a net negative charge. Proteins can, thus, be separated by net charge in a polyacrylamide gel using either preparative native PAGE, which uses a constant pH to separate proteins, or isoelectric focusing, which uses a pH gradient to separate proteins. Isoelectric focusing is the first step in 2-D polyacrylamide gel electrophoresis.
phase transition 1. A transformation of a chemical substance between solid, liquid, and gaseous states of matter and, in rare cases, plasma. 2. The measurable values of the external conditions at which such a transformation occurs.
Sources: en.wikipedia.org
In English, the term "America" (used without a qualifier) seldom refers to topics unrelated to the United States. "The Americas" is the general term to describe the totality of the continents of North and South America.
In the 1960s, the BOR Code of Ethics and Standards of Conduct placed professional limitations on medical technologists requiring "A medical technologist will work at all times under the direction or supervision of a pathologist or other duly qualified and licensed doctor of medicine, such qualifications being determined on the basis of accepted medical ethics" and that "A medical technologist will not act as owner, co-owner, advisor or employee, or by means of any subterfuge, participate in an arrangement whereby an individual not regularly licensed to practice medicine is enabled to own or operate a laboratory of clinical pathology." In 1965, Janet Higgins, an ASCP certified medical technologist, was removed from the Board of Registry (BOR) because she was employed at a New Jersey laboratory where the director was a state-licensed bio-analytical laboratory director, but not a physician. Though New Jersey has never required the certification for employment, the technologist successfully sued ASCP under monopolistic restraint of trade to be reinstated to the registry with the Supreme Court of New Jersey finding that the "professional status conferred on plaintiff by her certificate is an interest of sufficient substance to warrant the protection of the court." The lawsuit, and the focus on pathologists over medical technologists spurred other medical technologist societies, such as the American Society for Medical Technology (ASMT) to promote the creation of their own certifying boards.
=== Alcohols === Alcohols generally have weak molecular ion peaks due to the strong electronegativity of oxygen. “Alpha” cleavage is common due to the resonance stabilization. The largest alkyl group will be lost.
== Structural studies == As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1EJ2, PDB: 1GZU, PDB: 1HYB, PDB: 1KKU, PDB: 1KQN, PDB: 1KQO, PDB: 1KR2, PDB: 1M8F, PDB: 1M8G, PDB: 1M8J, and PDB: 1M8K.
Sources: en.wikipedia.org
=== On the Chinese social critics === As a reaction to and comment on the scandal, Chinese artist and video animation producer Pi San created "Little Rabbit, Be Good" as part of his popular Kuang Kuang video series. Though officially banned or forbidden by the Chinese government, clever use of Chinese web services such as Baidu allows Chinese citizens to access this and many other forbidden materials.
=== Early DNA sequencing methods === The first method for determining DNA sequences involved a location-specific primer extension strategy established by Ray Wu, a Chinese-born American geneticist, at Cornell University in 1970. DNA polymerase catalysis and specific nucleotide labeling, both of which figure prominently in current sequencing schemes, were used to sequence the cohesive ends of lambda phage DNA. Between 1970 and 1973, Wu, scientist Radha Padmanabhan, and colleagues demonstrated that this method can be employed to determine any DNA sequence using synthetic location-specific primers. Walter Gilbert, a biochemist, and Allan Maxam, a molecular geneticist, at Harvard also developed sequencing methods, including one for "DNA sequencing by chemical degradation". In 1973, Gilbert and Maxam reported the sequence of 24 basepairs using a method known as wandering-spot analysis. Advancements in sequencing were aided by the concurrent development of recombinant DNA technology, allowing DNA samples to be isolated from sources other than viruses. Two years later in 1975, Frederick Sanger, a biochemist, and Alan Coulson, a genome scientist, developed a method to sequence DNA. The technique known as the "Plus and Minus" method, involved supplying all the components of the DNA but excluding the reaction of one of the four bases needed to complete the DNA. In 1976, Gilbert and Maxam, invented a method for rapidly sequencing DNA while at Harvard, known as the Maxam–Gilbert sequencing.
== Manifestations of chirality == Flavor: the artificial sweetener aspartame has two enantiomers. L-aspartame tastes sweet whereas D-aspartame is tasteless. Odor: R-(–)-carvone smells like spearmint whereas S-(+)-carvone smells like caraway. Drug effectiveness: the antidepressant drug citalopram is sold as a racemic mixture. However, studies have shown that only the (S)-(+) enantiomer (escitalopram) is responsible for the drug's beneficial effects. Drug safety: D‑penicillamine is used in chelation therapy and for the treatment of rheumatoid arthritis whereas L‑penicillamine is toxic as it inhibits the action of pyridoxine, an essential B vitamin.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.